ArticleOncoimmunology
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Friedrich H Schmitz-Winnenthal et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
47 papers cite it
cites it